Clinical Trial Update: MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 trial evaluating MEDI-522 in patients with metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• MEDI-522

Snippet

Sponsor: MedImmune LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED